ProPhase Labs Validates BE-Smart Test; Study Demonstrates High Accuracy; Clinical Rollout Expected Within 2-3 Quarters

BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States

Study shows >95% success rate, validating BE-Smart for use with esophageal brush cytology.

ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today announced the successful completion of a key validation study evaluating the performance of the BE-Smart™ molecular diagnostic test compatibility with samples obtained from esophageal brush cytology. The study demonstrated BE-Smart™ achieved greater than a 95% technical success rate, confirming the BE-Smart's ability to reliably and accurately detect our panel of biomarkers, designed to assess progression risk in Barrett's esophagus and other distal esophageal conditions. Prophase will now move to accelerated commercialization of BE-Smart™ with expected clinical launch in the next 2-3 quarters.

BE-Smart uses a proprietary panel of biomarkers and a multi-modal analysis method which together significantly increase detection of deadly cancer cells in one of the fastest growing cancer indications, esophageal denocarcinoma cancer or "EAC". EAC has a 5-year mortality rate of over 79% and surged in annual incidence over 750% since the 1970s. BE-Smart represents a technical advance in detection and prognosis which has the potential to change cost and outcomes for the large population affected by GERD, Barrett's and EAC globally.